@article{SantoroLabopinGiannottietal.2018, author = {Santoro, Nicole and Labopin, Myriam and Giannotti, Federica and Ehninger, Gerard and Niederwieser, Dietger and Brecht, Arne and Stelljes, Matthias and Kr{\"o}ger, Nicolaus and Einsele, Herman and Eder, Matthias and Hallek, Michael and Glass, Bertram and Finke, J{\"u}rgen and Ciceri, Fabio and Mohty, Mohamad and Ruggeri, Annalisa and Nagler, Arnon}, title = {Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT}, series = {Journal of Hematology \& Oncology}, volume = {11}, journal = {Journal of Hematology \& Oncology}, doi = {10.1186/s13045-018-0598-0}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-227315}, pages = {55, 1-10}, year = {2018}, abstract = {Background: Acute myeloid leukemia (AML) is both more common and with more biologically aggressive phenotype in the elderly. Allogenic stem cell transplantation (allo-SCT) is the best treatment option in fit patients. Either HLA-matched unrelated donor (MUD) or haploidentical (Haplo) donor are possible alternative for patients in need. Methods: We retrospectively compared non-T-cell-depleted Haplo (n = 250) to 10/10 MUD (n = 2589) in AML patients >= 60 years. Results: Median follow-up was 23 months. Disease status at transplant differs significantly between the two groups (p < 10(-4)). Reduced intensity conditioning (RIC) was administrated to 73 and 77\% of Haplo and MUD, respectively (p = 0.23). Stem cell source was the bone marrow (BM) in 52\% of the Haplo and 6\% of MUD (p < 10(-4)). Anti-thymocyte globulin (ATG) was most frequently used in MUD (p < 10(-4)) while post-Tx cyclophosphamide (PT-Cy) was given in 62\% of Haplo. Engraftment was achieved in 90\% of the Haplo vs 97\% of MUD (p < 10(-4)). In multivariate analysis, no significant difference was found between Haplo and MUD for acute (a) graft versus host disease (GVHD) grade II-IV, relapse incidence (RI), non-relapse mortality (NRM), leukemia free survival (LFS), graft-versus-host-free-relapse free survival (GRFS), and overall survival (OS). Extensive chronic (c) GVHD was significantly higher for MUD as compared to Haplo (HR 2, p = 0.01, 95\% CI 1.17-3.47). A propensity score analysis confirmed the higher risk of extensive cGVHD for MUD without differences for other outcomes. Conclusions: Allo-SCT from both Haplo and MUD are valid option for AML patients >= 60 years of age with similar results. Transplantation from MUD was associated with higher extensive cGVHD. Our findings suggest that Haplo is a suitable and attractive graft source for patients >= 60 with AML in need of allo-SCT.}, language = {en} } @article{WernerWeichKircheretal.2018, author = {Werner, Rudolf A. and Weich, Alexander and Kircher, Malte and Solnes, Lilja B. and Javadi, Mehrbod S. and Higuchi, Takahiro and Buck, Andreas K. and Pomper, Martin G. and Rowe, Steven and Lapa, Constantin}, title = {The theranostic promise for neuroendocrine tumors in the late 2010s - Where do we stand, where do we go?}, series = {Theranostics}, volume = {8}, journal = {Theranostics}, number = {22}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-170264}, pages = {6088-6100}, year = {2018}, abstract = {More than 25 years after the first peptide receptor radionuclide therapy (PRRT), the concept of somatostatin receptor (SSTR)-directed imaging and therapy for neuroendocrine tumors (NET) is seeing rapidly increasing use. To maximize the full potential of its theranostic promise, efforts in recent years have expanded recommendations in current guidelines and included the evaluation of novel theranostic radiotracers for imaging and treatment of NET. Moreover, the introduction of standardized reporting framework systems may harmonize PET reading, address pitfalls in interpreting SSTR-PET/CT scans and guide the treating physician in selecting PRRT candidates. Notably, the concept of PRRT has also been applied beyond oncology, e.g. for treatment of inflammatory conditions like sarcoidosis. Future perspectives may include the efficacy evaluation of PRRT compared to other common treatment options for NET, novel strategies for closer monitoring of potential side effects, the introduction of novel radiotracers with beneficial pharmacodynamic and kinetic properties or the use of supervised machine learning approaches for outcome prediction. This article reviews how the SSTR-directed theranostic concept is currently applied and also reflects on recent developments that hold promise for the future of theranostics in this context.}, subject = {Positronen-Emissions-Tomografie}, language = {en} } @article{RolveringZimmerGinolhacetal.2018, author = {Rolvering, Catherine and Zimmer, Andreas D. and Ginolhac, Aur{\´e}lien and Margue, Christiane and Kirchmeyer, M{\´e}lanie and Servais, Florence and Hermanns, Heike M. and Hergovits, Sabine and Nazarov, Petr V. and Nicot, Nathalie and Kreis, Stephanie and Haan, Serge and Behrmann, Iris and Haan, Claude}, title = {The PD-L1-and IL6-mediated dampening of the IL27/STAT1 anticancer responses are prevented by alpha-PD-L1 or alpha-IL6 antibodies}, series = {Journal of Leukocyte Biology}, volume = {104}, journal = {Journal of Leukocyte Biology}, number = {5}, doi = {10.1002/JLB.MA1217-495R}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-226974}, pages = {969-985}, year = {2018}, abstract = {Interleukin-27 (IL27) is a type-I cytokine of the IL6/IL12 family and is predominantly secreted by activated macrophages and dendritic cells. We show that IL27 induces STAT factor phosphorylation in cancerous cell lines of different tissue origin. IL27 leads to STAT1 phosphorylation and recapitulates an IFN--like response in the microarray analyses, with up-regulation of genes involved in antiviral defense, antigen presentation, and immune suppression. Like IFN-, IL27 leads to an up-regulation of TAP2 and MHC-I proteins, which mediate increased tumor immune clearance. However, both cytokines also upregulate proteins such as PD-L1 (CD274) and IDO-1, which are associated with immune escape of cancer. Interestingly, differential expression of these genes was observed within the different cell lines and when comparing IL27 to IFN-. In coculture experiments of hepatocellular carcinoma (HCC) cells with peripheral blood mononuclear cells, pre-treatment of the HCC cells with IL27 resulted in lowered IL2 production by anti-CD3/-CD28 activated T-lymphocytes. Addition of anti-PD-L1 antibody, however, restored IL2 secretion. The levels of other T(H)1 cytokines were also enhanced or restored upon administration of anti-PD-L1. In addition, we show that the suppression of IL27 signaling by IL6-type cytokine pre-stimulationmimicking a situation occurring, for example, in IL6-secreting tumors or in tumor inflammation-induced cachexiacan be antagonized by antibodies against IL6-type cytokines or their receptors. Therapeutically, the antitumor effects of IL27 (mediated, e.g., by increased antigen presentation) might thus be increased by combining IL27 with blocking antibodies against PD-L1 or/and IL6-type cytokines.}, language = {en} } @article{GroebnerWorstWeischenfeldtetal.2018, author = {Gr{\"o}bner, Susanne N. and Worst, Barbara C. and Weischenfeldt, Joachim and Buchhalter, Ivo and Kleinheinz, Kortine and Rudneva, Vasilisa A. and Johann, Pascal D. and Balasubramanian, Gnana Prakash and Segura-Wang, Maia and Brabetz, Sebastian and Bender, Sebastian and Hutter, Barbara and Sturm, Dominik and Pfaff, Elke and H{\"u}bschmann, Daniel and Zipprich, Gideon and Heinold, Michael and Eils, J{\"u}rgen and Lawerenz, Christian and Erkek, Serap and Lambo, Sander and Waszak, Sebastian and Blattmann, Claudia and Borkhardt, Arndt and Kuhlen, Michaela and Eggert, Angelika and Fulda, Simone and Gessler, Manfred and Wegert, Jenny and Kappler, Roland and Baumhoer, Daniel and Stefan, Burdach and Kirschner-Schwabe, Renate and Kontny, Udo and Kulozik, Andreas E. and Lohmann, Dietmar and Hettmer, Simone and Eckert, Cornelia and Bielack, Stefan and Nathrath, Michaela and Niemeyer, Charlotte and Richter, G{\"u}nther H. and Schulte, Johannes and Siebert, Reiner and Westermann, Frank and Molenaar, Jan J. and Vassal, Gilles and Witt, Hendrik and Burkhardt, Birgit and Kratz, Christian P. and Witt, Olaf and van Tilburg, Cornelis M. and Kramm, Christof M. and Fleischhack, Gudrun and Dirksen, Uta and Rutkowski, Stefan and Fr{\"u}hwald, Michael and Hoff, Katja von and Wolf, Stephan and Klingebeil, Thomas and Koscielniak, Ewa and Landgraf, Pablo and Koster, Jan and Resnick, Adam C. and Zhang, Jinghui and Liu, Yanling and Zhou, Xin and Waanders, Angela J. and Zwijnenburg, Danny A. and Raman, Pichai and Brors, Benedikt and Weber, Ursula D. and Northcott, Paul A. and Pajtler, Kristian W. and Kool, Marcel and Piro, Rosario M. and Korbel, Jan O. and Schlesner, Matthias and Eils, Roland and Jones, David T. W. and Lichter, Peter and Chavez, Lukas and Zapatka, Marc and Pfister, Stefan M.}, title = {The landscape of genomic alterations across childhood cancers}, series = {Nature}, volume = {555}, journal = {Nature}, organization = {ICGC PedBrain-Seq Project, ICGC MMML-Seq Project,}, doi = {10.1038/nature25480}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-229579}, pages = {321-327}, year = {2018}, abstract = {Pan-cancer analyses that examine commonalities and differences among various cancer types have emerged as a powerful way to obtain novel insights into cancer biology. Here we present a comprehensive analysis of genetic alterations in a pan-cancer cohort including 961 tumours from children, adolescents, and young adults, comprising 24 distinct molecular types of cancer. Using a standardized workflow, we identified marked differences in terms of mutation frequency and significantly mutated genes in comparison to previously analysed adult cancers. Genetic alterations in 149 putative cancer driver genes separate the tumours into two classes: small mutation and structural/copy-number variant (correlating with germline variants). Structural variants, hyperdiploidy, and chromothripsis are linked to TP53 mutation status and mutational signatures. Our data suggest that 7-8\% of the children in this cohort carry an unambiguous predisposing germline variant and that nearly 50\% of paediatric neoplasms harbour a potentially druggable event, which is highly relevant for the design of future clinical trials.}, language = {en} } @article{BenoitScheurlenGoebeleretal.2018, author = {Benoit, Sandrine and Scheurlen, Michael and Goebeler, Matthias and Stoevesandt, Johanna}, title = {Structured diagnostic approach and risk assessment in mucous membrane pemphigoid with oesophageal involvement}, series = {Acta Dermato-Venereologica}, volume = {98}, journal = {Acta Dermato-Venereologica}, doi = {10.2340/00015555-2938}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-176191}, pages = {660-666}, year = {2018}, abstract = {Oesophageal involvement in mucous membrane pemphigoid is considered rare, but it may be underdiagnosed. To assess the incidence of oesophageal involvement in a group of patients with newly diagnosed mucous membrane pemphigoid we retrospectively analysed the medical records of 30 consecutive patients with mucous membrane pemphigoid diagnosed between 2006 and 2016 at the Department of Dermatology, University Hospital W{\"u}rzburg. Twenty-one patients (70\%) reported symptoms indicative of oesophageal mucous membrane pemphigoid. Twelve patients (40\%) underwent oesophagogastroduodenoscopy, and oesophageal pathology compatible with mucous membrane pemphigoid was endoscopically found in 9 cases (30\%). In all patients indirect and direct immunofluorescence were performed. Patients with and without oesophageal involvement did not differ with regard to the results of indirect immunofluorescence on salt-split human skin and monkey oesophagus. Study results demonstrate the necessity of a standardized diagnostic work-up, including adequate tissue samples for direct immunofluorescence, to prevent underdiagnosis of oesophageal mucous membrane pemphigoid.}, language = {en} } @article{WernerSolnesJavadietal.2018, author = {Werner, Rudolf and Solnes, Lilja and Javadi, Mehrbod and Weich, Alexander and Gorin, Michael and Pienta, Kenneth and Higuchi, Takahiro and Buck, Andreas and Pomper, Martin and Rowe, Steven and Lapa, Constantin}, title = {SSTR-RADS Version 1.0 as a Reporting System for SSTR-PET Imaging and Selection of Potential PRRT Candidates: A Proposed Standardization Framework}, series = {Journal of Nuclear Medicine}, journal = {Journal of Nuclear Medicine}, issn = {0161-5505}, doi = {10.2967/jnumed.117.206631}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-161298}, year = {2018}, abstract = {Reliable standards and criteria for somatostatin receptor (SSTR) positron emission tomography (PET) are still lacking. We herein propose a structured reporting system on a 5-point scale for SSTR-PET imaging, titled SSTR-RADS version 1.0, which might serve as a standardized assessment for both diagnosis and treatment planning in neuroendocrine tumors (NET). SSTR-RADS could guide the imaging specialist in interpreting SSTR-PET scans, facilitate communication with the referring clinician so that appropriate work-up for equivocal findings is pursued, and serve as a reliable tool for patient selection for planned Peptide Receptor Radionuclide Therapy.}, subject = {Standardisierung}, language = {en} } @article{AnanyKreckelFuellsacketal.2018, author = {Anany, Mohamed A. and Kreckel, Jennifer and F{\"u}llsack, Simone and Rosenthal, Alevtina and Otto, Christoph and Siegmund, Daniela and Wajant, Harald}, title = {Soluble TNF-like weak inducer of apoptosis (TWEAK) enhances poly(I:C)-induced RIPK1-mediated necroptosis}, series = {Cell Death \& Disease}, volume = {9}, journal = {Cell Death \& Disease}, doi = {10.1038/s41419-018-1137-1}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-221104}, year = {2018}, abstract = {TNF-like weak inducer of apoptosis (TWEAK) and inhibition of protein synthesis with cycloheximide (CHX) sensitize for poly(I:C)-induced cell death. Notably, although CHX preferentially enhanced poly(I:C)-induced apoptosis, TWEAK enhanced primarily poly(I:C)-induced necroptosis. Both sensitizers of poly(I:C)-induced cell death, however, showed no major effect on proinflammatory poly(I:C) signaling. Analysis of a panel of HeLa-RIPK3 variants lacking TRADD, RIPK1, FADD, or caspase-8 expression revealed furthermore similarities and differences in the way how poly(I:C)/TWEAK, TNF, and TRAIL utilize these molecules for signaling. RIPK1 turned out to be essential for poly(I:C)/TWEAK-induced caspase-8-mediated apoptosis but was dispensable for this response in TNF and TRAIL signaling. TRADD-RIPK1-double deficiency differentially affected poly(I:C)-triggered gene induction but abrogated gene induction by TNF completely. FADD deficiency abrogated TRAIL- but not TNF- and poly(I:C)-induced necroptosis, whereas TRADD elicited protective activity against all three death inducers. A general protective activity against poly(I:C)-, TRAIL-, and TNF-induced cell death was also observed in FLIPL and FLIPS transfectrants.}, language = {en} } @article{RauSchmittBergetal.2018, author = {Rau, Monika and Schmitt, Johannes and Berg, Thomas and Kremer, Andreas E. and Stieger, Bruno and Spanaus, Katharina and Bengsch, Bertram and Romero, Marta R. and Marin, Jose J. and Keitel, Verena and Klinker, Hartwig and Tony, Hans-Peter and M{\"u}llhaupt, Beat and Geier, Andreas}, title = {Serum IP-10 levels and increased DPPIV activity are linked to circulating CXCR3+ T cells in cholestatic HCV patients}, series = {PLoS ONE}, volume = {13}, journal = {PLoS ONE}, number = {12}, doi = {10.1371/journal.pone.0208225}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-177674}, pages = {e0208225}, year = {2018}, abstract = {Background \& aims Serum interferon-gamma-inducible protein-10 (IP-10) is elevated in cholestatic liver diseases and predicts response to antiviral therapy in patients with chronic hepatitis C virus (HCV) infection. Dipeptidylpeptidase 4 (DPPIV) cleaves active IP-10 into an inactive form, which inhibits recruitment of CXCR3+ T cells to the liver. In this study the link between IP-10 levels, DPPIV activity in serum and CXCR3+ T cells is analysed in cholestatic and non-cholestatic liver patients. Methods In serum DPPIV activity (by enzymatic assay), IP-10 (by ELISA) and bile acids (BA) (by enzymatic assay) were analysed in 229 naive HCV genotype (GT) 1 patients and in 16 patients with cholestatic liver disease. In a prospective follow-up (FU) cohort of 27 HCV GT 1 patients peripheral CD3+CXCR3+, CD4+CXCR3+ and CD8+CXCR3+ cells were measured by FACS. Results In 229 HCV patients serum IP-10 levels correlated positively to DPPIV serum activity. Higher IP-10 levels and DPPIV activity were detected in cholestatic and in cirrhotic HCV patients. Increased IP-10 serum levels were associated with therapeutic non-response to antiviral treatment with pegylated-interferon and ribavirin. In the HCV FU cohort elevated IP-10 serum levels and increased BA were associated with higher frequencies of peripheral CD3+CXCR3+, CD4+CXCR3+ and CD8+CXCR3+ T cells. Positive correlation between serum IP-10 levels and DPPIV activity was likewise validated in patients with cholestatic liver diseases. Conclusions A strong correlation between elevated serum levels of IP-10 and DPPIV activity was seen in different cholestatic patient groups. Furthermore, in cholestatic HCV patients a functional link to increased numbers of peripheral CXCR3+ immune cells could be observed. The source of DPPIV release in cholestatic patients remains open.}, language = {en} } @article{KnoedlerKoerferKunzmannetal.2018, author = {Kn{\"o}dler, Maren and K{\"o}rfer, Justus and Kunzmann, Volker and Trojan, J{\"o}rg and Daum, Severin and Schenk, Michael and Kullmann, Frank and Schroll, Sebastian and Behringer, Dirk and Stahl, Michael and Al-Batran, Salah-Eddin and Hacker, Ulrich and Ibach, Stefan and Lindhofer, Horst and Lordick, Florian}, title = {Randomised phase II trial to investigate catumaxomab (anti-EpCAM × anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer}, series = {British Journal of Cancer}, volume = {119}, journal = {British Journal of Cancer}, doi = {10.1038/s41416-018-0150-6}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-325938}, pages = {296-302}, year = {2018}, abstract = {Background Peritoneal carcinomatosis (PC) represents an unfavourable prognostic factor for patients with gastric cancer (GC). Intraperitoneal treatment with the bispecific and trifunctional antibody catumaxomab (EpCAM, CD3), in addition to systemic chemotherapy, could improve elimination of PC. Methods This prospective, randomised, phase II study investigated the efficacy of catumaxomab followed by chemotherapy (arm A, 5-fluorouracil, leucovorin, oxaliplatin, docetaxel, FLOT) or FLOT alone (arm B) in patients with GC and PC. Primary endpoint was the rate of macroscopic complete remission (mCR) of PC at the time of second diagnostic laparoscopy/laparotomy prior to optional surgery. Results Median follow-up was 52 months. Out of 35 patients screened, 15 were allocated to arm A and 16 to arm B. mCR rate was 27\% in arm A and 19\% in arm B (p = 0.69). Severe side effects associated with catumaxomab were nausea, infection, abdominal pain, and elevated liver enzymes. Median progression-free (6.7 vs. 5.4 months, p = 0.71) and overall survival (13.2 vs. 13.0 months, p = 0.97) were not significantly different in both treatment arms. Conclusions Addition of catumaxomab to systemic chemotherapy was feasible and tolerable in advanced GC. Although the primary endpoint could not be demonstrated, results are promising for future investigations integrating intraperitoneal immunotherapy into a multimodal treatment strategy.}, language = {en} } @phdthesis{Hefter2018, author = {Hefter, Maike Sina}, title = {Quantifizierung und funktionale Analysen von \(Aspergillus\)-spezifischen Rezeptoren auf humanen dendritischen Zell-Subpopulationen}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-166636}, school = {Universit{\"a}t W{\"u}rzburg}, year = {2018}, abstract = {Pilzinfektionen z{\"a}hlen zu den h{\"a}ufigsten Infektionen beim Menschen. Sie verlaufen in den meisten F{\"a}llen unkompliziert und stellen keine vitale Bedrohung f{\"u}r den Betroffenen dar. Invasive Mykosen hingegen verlaufen oft t{\"o}dlich und sind eine große Herausforderung f{\"u}r die moderne Medizin, da eine fr{\"u}he Diagnose schwierig ist und die therapeutischen M{\"o}glichkeiten limitiert sind. Die Invasive Aspergillose (IA) z{\"a}hlt mit gesch{\"a}tzt {\"u}ber 200.000 Infektionen pro Jahr weltweit zu einer der h{\"a}ufigsten Invasiven Mykosen. Die bekanntesten Risikofaktoren f{\"u}r die Entstehung einer IA sind die Neutropenie, Organtransplantationen, h{\"a}matopoetische Stammzelltransplantationen und Erkrankungen, die mit einer Kompromittierung des Immunsystems einhergehen. Erreger der Invasiven Aspergillose ist in nahezu 90 Prozent Aspergillus fumigatus (A. fumigatus), ein ubiquit{\"a}r vorkommender Schimmelpilz. Seine Verbreitung erfolgt aerogen durch Sporen, sogenannte Konidien, die aufgrund ihres geringen Durchmessers problemlos {\"u}ber die Atemwege in die Lunge gelangen k{\"o}nnen. Dendritische Zellen spielen als professionelle Antigen pr{\"a}sentierende Zellen eine wichtige Rolle in der Immunabwehr gegen A. fumigatus. Sie sind ein wichtiges Bindeglied zwischen angeborenem und adaptivem Immunsystem und sind mit einer Vielzahl von Rezeptoren (engl. pattern recognition receptor, PRR) zur Pathogen Erkennung ausgestattet. In der vorliegenden Arbeit wurde die Interaktion ausgew{\"a}hlter C Typ Lektin (CLEC) Rezeptoren auf Subtypen dendritischer Zellen (DCs) mit verschiedenen A. fumigtaus Morphologien untersucht. Es wurde mit in vitro generierten Monozyten abgeleiteten (moDCs) und in vivo vorkommenden myeloiden dendritischen Zellen (mDCs) gearbeitet und die Expression von CLEC4A, CLEC6A, CLEC7A, CLEC12A und CLEC4E und eine m{\"o}gliche Regulation der Rezeptoren nach Stimulation mit Konidien, geschwollenen Konidien oder Keimschl{\"a}uchen untersucht. Hierbei wurde bei beiden Subtypen eine Herabregulation von CLEC4A, CLEC7A und CLEC12A beobachtet. Dies ist vereinbar mit der Tatsache, dass C Typ Lektin Rezeptoren nicht nur eine Rolle bei der Pathogen Erkennung spielen, sondern auch als Phagozytose Rezeptoren fungieren. Auf molekularbiologischer Ebene wurde in Analysen von moDCs ebenfalls eine Reduktion der relativen mRNA Expression von CLEC4A, CLEC6A, CLEC7A und CLEC12A beobachtet. Weiterhin wurden die Auswirkungen einer Rezeptorblockade von CLEC7A mittels blockierender Antik{\"o}rper auf das Maturierungsverhalten und Zytokinprofil beider Subtypen analysiert. Hier konnte durch die Zugabe eines CLEC7A blockierenden Antik{\"o}rpers vor Stimulation mit A. fumigatus Konidien oder depletiertem Zymosan die Maturierung effektiv inhibiert werden. Die Sekretion der pro inflammatorischen Zytokine Tumornekrosefaktor α, Interleukin 8 und 1β, als auch des anti inflammatorischen Zytokins Interleukin 10 war durch die Rezeptorblockade ebenfalls signifikant vermindert. Diese Erkenntnisse st{\"u}tzen die bislang relativ gut untersuchte Rolle von CLEC7A auf Monozyten abgeleiteten dendritischen Zellen als spezifischen Rezeptor f{\"u}r A. fumigatus. Dar{\"u}ber hinaus konnte im Rahmen dieser Arbeit gezeigt werden, dass CLEC7A ebenfalls auf mDCs an der Erkennung von A. fumigatus und Initiierung einer Immunantwort beteiligt ist. Diese Tatsache ist von Bedeutung, da die beiden Subtypen nicht ohne weiteres miteinander verglichen werden k{\"o}nnen und die Relevanz von in vivo vorkommen myeloiden dendritischen Zellen an einer Immunantwort gegen A. fumigatus bislang noch viele Fragen offen l{\"a}sst. Es bedarf weiterer Untersuchungen, insbesondere funktionaler Analysen von intrazellul{\"a}ren Signalwegen um ein besseres Verst{\"a}ndnis zu erlangen. Die {\"U}bertragung in ein Tiermodell und die gezielte Ausschaltung von C Typ Lektin Rezeptor Genen k{\"o}nnte ein Ausblick auf zuk{\"u}nftige Forschungsprojekte sein.}, subject = {Aspergillus fumigatus}, language = {de} }